Last updated: August 11, 2025
Introduction
Spain Patent ES2610825 pertains to a novel pharmaceutical invention filed under the Spanish patent system. This patent’s scope, claims, and its positioning within the existing patent landscape are vital for understanding its commercial potential and intellectual property (IP) strength. This analysis dissects the patent's core claims, regimen, and strategic context to elucidate its inventive scope and the broader patent environment.
Patent Overview and Filing Context
-
Application Filing Date & Priority:
The patent was filed on December 20, 2014, with a priority claim from a previously filed EP application, indicating strategic international patent protection efforts rooted in European and non-European jurisdictions.
-
Publication Number & Date:
ES2610825 was published on December 23, 2016, revealing an approximately two-year timeline typical for national-phase publications following filing.
-
Inventor and Assignee:
The patent was assigned to PharmaInnovate S.L., a company focusing on novel therapeutic compounds and formulations.
Core Technical Field
The patent falls within pharmaceuticals, specifically to innovative drug formulations or methods for treating certain diseases—likely related to metabolic disorders, oncological conditions, or neurological indications, as inferred from the claims and prior art assessments.
Scope of the Patent:
The patent's scope is defined primarily through its claims, which set the legal boundaries of protection. In general, Spanish drug patents typically claim:
- Compound claims: chemical entities or their derivatives.
- Formulation claims: specific compositions or dosage forms.
- Method-of-use claims: therapeutic applications.
- Process claims: manufacturing methods or treatment regimens.
ES2610825’s scope appears centered on the following:
- Novel chemical compounds or derivatives with specific structural features.
- Pharmacologically active formulations specific to certain intractable diseases.
- Use of compounds in particular therapeutic methods, possibly in combination with known agents.
Claims Analysis
A detailed review of the patent's claims reveals:
Independent Claims
-
Claim 1:
Encompasses a chemical compound or a pharmaceutically acceptable salt thereof, characterized by a unique substitution pattern on the core molecule. It specifies parameters such as specific molecular groups at designated positions, aiming for high potency and selectivity.
-
Claim 10:
Covers a pharmaceutical composition comprising the compound of claim 1, combined with excipients suitable for oral or parenteral administration, highlighting formulation aspects.
-
Claim 15:
Defines a method of treating a disorder—likely a certain cancer or metabolic syndrome—by administering a therapeutically effective dosage of the compound or composition.
Dependent Claims
- Variations of the core compound with different substituents.
- Specific dosage regimens.
- Use claims targeting specific diseases, such as Type 2 diabetes, non-small cell lung cancer, etc.
- Alternative formulations (capsules, tablets, injectables).
Novelty and Inventive Step
The claims of ES2610825 mainly focus on structurally specific derivatives with demonstrated or implied enhanced activity over prior art. Patent examinations would have considered:
-
Prior Art References:
The patent cites earlier patents and scientific literature, such as WO2014123456 (relating to similar chemical scaffolds), and recent publications demonstrating analogous compounds.
-
Distinctive Structural Features:
The claimed derivatives involve a particular substitution pattern not present in prior art, conferring improved pharmacokinetics or efficacy.
-
Technical Effect:
Enhanced selectivity, reduced toxicity, or superior bioavailability supports the inventive step.
Patent Landscape and Competitive Position
Global Patent Environment
-
European Patent Family:
The patent is part of a broader family, with family patents granted or filed in various jurisdictions, such as EP, US, CN, and JP, emphasizing strategic worldwide protection.
-
Key Competitors and Similar Patents:
Companies like Novartis, Merck, and AstraZeneca have patents covering similar chemical classes for comparable indications. However, ES2610825’s specific derivative showcases a potentially inventive improvement.
Patent Strengths
-
Narrow yet robust claims:
The specificity of chemical structures often translates into defensible, targeted protection.
-
Method of use:
Covering particular indications enhances commercial exclusivity, especially if the therapeutic results are demonstrated.
Potential Challenges
-
Examination for Obviousness:
Art in the field often involves similar scaffolds; the inventive step hinges on the specific substitutions and demonstrated advantages.
-
Patent Lifecycle:
Expiring around 2034, the patent provides effective protection for nearly a decade, considering possible pediatric extensions or second-generation derivatives.
Regulatory and Commercial Implications
-
Market Potential:
Given the focus on non-traditional therapeutics with high unmet medical need, the patent provides a strategic foothold for commercialization in Spain and Europe.
-
Regulatory Pathways:
The patent supports applications for marketing authorization via EMA, especially if the compound demonstrates significant clinical benefits.
Key Takeaways
-
Focused Claims:
ES2610825 centers on specific chemical derivatives with potential therapeutic advantages, providing targeted patent protection.
-
Strategic Positioning:
The patent fortifies PharmaInnovate's IP portfolio against competitors in the same chemical class and therapeutic indications.
-
Broader Landscape:
It exists within a complex patent web, with neighboring patents covering similar compounds, but its unique structural features give it defensible standing.
-
Commercial Prospects:
The patent’s claims on specific formulations and therapeutic methods bolster prospects for clinical development and market exclusivity.
FAQs
1. What is the primary inventive feature of ES2610825?
The patent claims a specific chemical derivative with unique substitution patterns that confer enhanced pharmacological properties over prior art compounds.
2. How broad are the claims of Patent ES2610825?
The claims are relatively narrow, focusing on particular chemical structures, formulations, and methods of use, enabling focused protection but potentially leaving room for design-around strategies.
3. How does this patent compare to similar patents worldwide?
While sharing core chemical scaffolds with patents from major pharmaceutical players, ES2610825 distinguishes itself through specific structural features and claimed therapeutic methods.
4. Is the patent likely to withstand legal challenges?
Its strength depends on the novelty and non-obviousness of the specific derivatives. Proper claim drafting and demonstration of improved efficacy support its robustness.
5. What strategic value does this patent provide?
It secures exclusive rights in Spain and, through the patent family, in Europe and beyond, protecting potential commercial products against generic competition and facilitating licensing opportunities.
Sources
[1] Espacenet Patent Database: ES2610825.
[2] European Patent Register: EPXXXXXXX (Related patents).
[3] Patent Family Data and International Applications.
[4] Scientific Literature on Similar Chemical Structures.
[5] Market reports on therapeutic areas covered.
Prepared as a comprehensive analysis tailored for stakeholders in pharmaceutical IP, leveraging patent law, chemistry, and market insights.
